19,343 Johnson & Johnson $JNJ Shares Sold by AEGON ASSET MANAGEMENT UK Plc

Key Points

• AEGON Asset Management UK cut its Johnson & Johnson stake by 4.4%, selling 19,343 shares in the third quarter; it retained 424,360 shares valued at about $112.3 million.
• Analysts have a consensus “Moderate Buy” rating and an average price target of $275.92. Recent ratings included raised targets from Wells Fargo and JPMorgan.
• J&J beat quarterly EPS estimates, reporting $2.59 per share, while revenue rose 5.9% year over year to $25.4 billion.

AEGON ASSET MANAGEMENT UK Plc cut its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 4.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 424,360 shares of the company's stock after selling 19,343 shares during the quarter. Johnson & Johnson comprises 1.2% of AEGON ASSET MANAGEMENT UK Plc's investment portfolio, making the stock its 21st biggest position. AEGON ASSET MANAGEMENT UK Plc's holdings in Johnson & Johnson were worth $112,345,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Gryphon Financial Partners LLC grew its stake in Johnson & Johnson by 0.5% during the 3rd quarter. Gryphon Financial Partners LLC now owns 25,964 shares of the company's stock valued at $6,874,000 after acquiring an additional 139 shares in the last quarter. AlphaCore Capital LLC raised its holdings in Johnson & Johnson by 17.7% in the 3rd quarter. AlphaCore Capital LLC now owns 59,109 shares of the company's stock valued at $15,649,000 after acquiring an additional 8,883 shares during the last quarter. Leuthold Group LLC lifted its stake in Johnson & Johnson by 9.5% in the 3rd quarter. Leuthold Group LLC now owns 34,031 shares of the company's stock worth $9,009,000 after purchasing an additional 2,946 shares in the last quarter. Palacios Wealth Management LLC purchased a new position in Johnson & Johnson in the 3rd quarter worth approximately $234,000. Finally, Clear Wave Wealth Management LLC boosted its holdings in shares of Johnson & Johnson by 2.0% during the 3rd quarter. Clear Wave Wealth Management LLC now owns 5,191 shares of the company's stock worth $1,374,000 after purchasing an additional 100 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, EVP Timothy Schmid sold 33,597 shares of the company's stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the transaction, the executive vice president owned 25,447 shares of the company's stock, valued at $6,991,308.78. This represents a 56.90% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Jennifer Taubert sold 15,000 shares of the stock in a transaction on Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the transaction, the executive vice president owned 194,451 shares of the company's stock, valued at approximately $51,210,615.36. This represents a 7.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.16% of the stock is owned by insiders.

Analyst Ratings Changes

JNJ has been the subject of a number of analyst reports. Wells Fargo & Company upped their price target on Johnson & Johnson from $275.00 to $287.00 and gave the company an "overweight" rating in a research report on Friday, October 16th. JPMorgan Chase & Co. lifted their price objective on Johnson & Johnson from $270.00 to $285.00 and gave the stock a "neutral" rating in a research report on Tuesday, September 29th. Wall Street Zen lowered Johnson & Johnson from a "buy" rating to a "hold" rating in a research note on Saturday, August 1st. Stifel Nicolaus set a $260.00 price objective on Johnson & Johnson in a research note on Wednesday, July 15th. Finally, Guggenheim restated a "buy" rating and issued a $287.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 7th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $275.92.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: In a first-in-human Phase 1 study, the investigational pasritamig–JNJ-9401 combination produced a PSA reduction of at least 50% in 11 of 15 patients with advanced prostate cancer; nearly half had reductions of at least 90%. J&J reported an encouraging safety profile and said the regimen is advancing toward Phase 3, though the small early-stage study carries substantial uncertainty. Article: Johnson & Johnson reports 73% PSA response rate
• Positive Sentiment: ICOTYDE (icotrokinra) met the primary endpoint in a Phase 3 trial in biologic-naive patients with psoriatic arthritis, supporting the potential of this once-daily oral treatment. Article: ICOTYDE meets primary endpoint in Phase 3 study
• Positive Sentiment: J&J also presented new nipocalimab data in Sjögren’s disease and reported positive results for autoimmune therapies at a medical meeting, adding to the pipeline’s potential, although the reports provide limited detail on commercial impact. Article: New Phase 2 nipocalimab study data
• Negative Sentiment: ETF investors were net sellers of J&J shares on Nov. 5, a modestly negative flow signal that predates the latest trial announcements. Article: ETFs are net sellers of Johnson & Johnson

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $281.86 on Tuesday. The company's 50-day moving average is $266.18 and its two-hundred day moving average is $248.62. Johnson & Johnson has a 1-year low of $185.12 and a 1-year high of $282.73. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.02 and a quick ratio of 0.74. The firm has a market capitalization of $678.53 billion, a price-to-earnings ratio of 25.95, a PEG ratio of 2.73 and a beta of 0.22.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The business had revenue of $25.40 billion during the quarter, compared to the consensus estimate of $25.38 billion. During the same quarter last year, the firm earned $2.80 EPS. The business's revenue was up 5.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Analysts forecast that Johnson & Johnson will post 11.12 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be paid a dividend of $1.34 per share. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 annualized dividend and a yield of 1.9%. Johnson & Johnson's dividend payout ratio (DPR) is 81.21%.

About Johnson & Johnson

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech.

Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care.

Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.